CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Price & Overview
NASDAQ:CNTA • US1523091007
Current stock price
The current stock price of CNTA is 28.3 USD. Today CNTA is down by -0.14%. In the past month the price increased by 13.54%. In the past year, price increased by 79.94%.
CNTA Key Statistics
- Market Cap
- 4.183B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.57
- Dividend Yield
- N/A
CNTA Stock Performance
CNTA Stock Chart
CNTA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CNTA. When comparing the yearly performance of all stocks, CNTA is one of the better performing stocks in the market, outperforming 92.24% of all stocks.
CNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTA. The financial health of CNTA is average, but there are quite some concerns on its profitability.
CNTA Earnings
CNTA Forecast & Estimates
22 analysts have analysed CNTA and the average price target is 40.41 USD. This implies a price increase of 42.78% is expected in the next year compared to the current price of 28.3.
CNTA Groups
Sector & Classification
CNTA Financial Highlights
Over the last trailing twelve months CNTA reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS decreased by -2.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.14% | ||
| ROE | -80.48% | ||
| Debt/Equity | 0.36 |
CNTA Ownership
CNTA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.87 | 364.65B | ||
| AMGN | AMGEN INC | 15.19 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.6 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.52 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.37 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.32 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.53 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.34 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNTA
Company Profile
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 114 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Company Info
IPO: 2021-05-28
CENTESSA PHARMACEUTICALS-ADR
3rd Floor, 1 Ashley Road
Altrincham CHESHIRE GB
CEO: Saurabh Saha
Employees: 114
Phone: 447391789784
CENTESSA PHARMACEUTICALS-ADR / CNTA FAQ
What does CENTESSA PHARMACEUTICALS-ADR do?
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 114 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
What is the stock price of CENTESSA PHARMACEUTICALS-ADR today?
The current stock price of CNTA is 28.3 USD. The price decreased by -0.14% in the last trading session.
What is the dividend status of CENTESSA PHARMACEUTICALS-ADR?
CNTA does not pay a dividend.
How is the ChartMill rating for CENTESSA PHARMACEUTICALS-ADR?
CNTA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for CENTESSA PHARMACEUTICALS-ADR?
CENTESSA PHARMACEUTICALS-ADR (CNTA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for CENTESSA PHARMACEUTICALS-ADR?
CENTESSA PHARMACEUTICALS-ADR (CNTA) currently has 114 employees.
When does CENTESSA PHARMACEUTICALS-ADR (CNTA) report earnings?
CENTESSA PHARMACEUTICALS-ADR (CNTA) will report earnings on 2026-03-23, after the market close.